169 related articles for article (PubMed ID: 8504423)
21. Phase I and correlative study of combination bryostatin 1 and vincristine in relapsed B-cell malignancies.
Dowlati A; Lazarus HM; Hartman P; Jacobberger JW; Whitacre C; Gerson SL; Ksenich P; Cooper BW; Frisa PS; Gottlieb M; Murgo AJ; Remick SC
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5929-35. PubMed ID: 14676117
[TBL] [Abstract][Full Text] [Related]
22. Varied differentiation responses of human leukemias to bryostatin 1.
Kraft AS; William F; Pettit GR; Lilly MB
Cancer Res; 1989 Mar; 49(5):1287-93. PubMed ID: 2917358
[TBL] [Abstract][Full Text] [Related]
23. A sensitive platelet activation-based functional assay for the antileukemic agent bryostatin 1.
Carr ME; Carr SL; Grant S
Anticancer Drugs; 1995 Jun; 6(3):384-91. PubMed ID: 7670135
[TBL] [Abstract][Full Text] [Related]
24. Protein kinase C activation without membrane contact in platelets stimulated by bryostatin.
Grabarek J; Ware JA
J Biol Chem; 1993 Mar; 268(8):5543-9. PubMed ID: 8449916
[TBL] [Abstract][Full Text] [Related]
25. Bryostatin 1/ionomycin (B/I) ex vivo stimulation preferentially activates L-selectinlow tumor-sensitized lymphocytes.
Chin CS; Miller CH; Graham L; Parviz M; Zacur S; Patel B; Duong A; Bear HD
Int Immunol; 2004 Sep; 16(9):1283-94. PubMed ID: 15262898
[TBL] [Abstract][Full Text] [Related]
26. Comparison of the antitumor activity of bryostatins 1, 5, and 8.
Kraft AS; Woodley S; Pettit GR; Gao F; Coll JC; Wagner F
Cancer Chemother Pharmacol; 1996; 37(3):271-8. PubMed ID: 8529289
[TBL] [Abstract][Full Text] [Related]
27. Contrasting duration of inhibition of cell-cell communication in primary mouse epidermal cells by phorbol 12,13-dibutyrate and by bryostatin 1.
Pasti G; Rivedal E; Yuspa SH; Herald CL; Pettit GR; Blumberg PM
Cancer Res; 1988 Jan; 48(2):447-51. PubMed ID: 3422054
[TBL] [Abstract][Full Text] [Related]
28. Bryostatin-1 stimulates the transcription of cyclooxygenase-2: evidence for an activator protein-1-dependent mechanism.
De Lorenzo MS; Yamaguchi K; Subbaramaiah K; Dannenberg AJ
Clin Cancer Res; 2003 Oct; 9(13):5036-43. PubMed ID: 14581379
[TBL] [Abstract][Full Text] [Related]
29. Regulation of motility and protease expression in PKC-mediated induction of MCF-7 breast cancer cell invasiveness.
Johnson MD; Torri JA; Lippman ME; Dickson RB
Exp Cell Res; 1999 Feb; 247(1):105-13. PubMed ID: 10047452
[TBL] [Abstract][Full Text] [Related]
30. Effects of bryostatin-1 on chronic myeloid leukaemia-derived haematopoietic progenitors.
Thijsen SF; Schuurhuis GJ; van Oostveen JW; Theijsmeijer AP; van der Hem KG; Odding JH; Dräger AM; Ossenkoppele GJ
Br J Cancer; 1999 Mar; 79(9-10):1406-12. PubMed ID: 10188883
[TBL] [Abstract][Full Text] [Related]
31. Evidence of a functional role for the cyclin-dependent kinase inhibitor p21(WAF1/CIP1/MDA6) in the reciprocal regulation of PKC activator-induced apoptosis and differentation in human myelomonocytic leukemia cells.
Wang Z; Su ZZ; Fisher PB; Wang S; VanTuyle G; Grant S
Exp Cell Res; 1998 Oct; 244(1):105-16. PubMed ID: 9770354
[TBL] [Abstract][Full Text] [Related]
32. Characterization of the protein kinase C signal transduction pathway in cisplatin-sensitive and -resistant human small cell lung carcinoma cells.
Basu A; Weixel K; Saijo N
Cell Growth Differ; 1996 Nov; 7(11):1507-12. PubMed ID: 8930400
[TBL] [Abstract][Full Text] [Related]
33. Simplified analogs of bryostatin with anticancer activity display greater potency for translocation of PKCdelta-GFP.
Baryza JL; Brenner SE; Craske ML; Meyer T; Wender PA
Chem Biol; 2004 Sep; 11(9):1261-7. PubMed ID: 15380186
[TBL] [Abstract][Full Text] [Related]
34. Successful treatment of human chronic lymphocytic leukemia xenografts with combination biological agents auristatin PE and bryostatin 1.
Mohammad RM; Varterasian ML; Almatchy VP; Hannoudi GN; Pettit GR; Al-Katib A
Clin Cancer Res; 1998 May; 4(5):1337-43. PubMed ID: 9607595
[TBL] [Abstract][Full Text] [Related]
35. Structural modifications of bryostatin 2.
Pettit GR; Sengupta D; Blumberg PM; Lewin NE; Schmidt JM; Kraft AS
Anticancer Drug Des; 1992 Apr; 7(2):101-14. PubMed ID: 1575884
[TBL] [Abstract][Full Text] [Related]
36. A simple analogue of tumor-promoting aplysiatoxin is an antineoplastic agent rather than a tumor promoter: development of a synthetically accessible protein kinase C activator with bryostatin-like activity.
Nakagawa Y; Yanagita RC; Hamada N; Murakami A; Takahashi H; Saito N; Nagai H; Irie K
J Am Chem Soc; 2009 Jun; 131(22):7573-9. PubMed ID: 19449873
[TBL] [Abstract][Full Text] [Related]
37. 1alpha,25-dihydroxyvitamin D3 and bryostatin-1 synergize to induce monocytic differentiation of NB4 acute promyelocytic leukemia cells by modulating cell cycle progression.
Clark CS; Konyer JE; Meckling KA
Exp Cell Res; 2004 Mar; 294(1):301-11. PubMed ID: 14980523
[TBL] [Abstract][Full Text] [Related]
38. A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma.
Blackhall FH; Ranson M; Radford JA; Hancock BW; Soukop M; McGown AT; Robbins A; Halbert G; Jayson GC;
Br J Cancer; 2001 Feb; 84(4):465-9. PubMed ID: 11263437
[TBL] [Abstract][Full Text] [Related]
39. Weekly bryostatin-1 in metastatic renal cell carcinoma: a phase II study.
Haas NB; Smith M; Lewis N; Littman L; Yeslow G; Joshi ID; Murgo A; Bradley J; Gordon R; Wang H; Rogatko A; Hudes GR
Clin Cancer Res; 2003 Jan; 9(1):109-14. PubMed ID: 12538458
[TBL] [Abstract][Full Text] [Related]
40. A Phase I trial of bryostatin-1 in children with refractory solid tumors: a Pediatric Oncology Group study.
Weitman S; Langevin AM; Berkow RL; Thomas PJ; Hurwitz CA; Kraft AS; Dubowy RL; Smith DL; Bernstein M
Clin Cancer Res; 1999 Sep; 5(9):2344-8. PubMed ID: 10499603
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
